Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00610727Phase 1Completed

Staccato Prochlorperazine Single Dose PK Study

Role: lead

NCT00603980Phase 1Completed

Staccato Alprazolam Abuse Liability

Role: lead

NCT00874237Phase 1Completed

Staccato Loxapine Thorough QT/QTc Study

Role: lead

NCT02351115Phase 2Completed

Staccato Alprazolam and Photoparoxysmal Response

Role: lead

NCT04200092Phase 1Completed

Staccato® Granisetron Single Dose PK

Role: lead

All 5 trials loaded